Public Company Healthcare

Core One Labs

Vancouver, British Columbia, Canada

Biotechnology company advancing psychedelic-assisted psychotherapy and thin-film oral delivery approaches, and producing API-grade psilocybin for clinical and research use.

Focus Areas
Psychedelic therapeutics, Biopharmaceutical R&D, Synthetic psilocybin production
Website
core1labs.com

Tracked deals

3

3 tracked deals across 2021-2022.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Core One Labs Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Core One Labs. 2 2021 1 2022

Supporting Data

Recent Transactions

  • Core One Labs Acquires Awakened Biosciences
    February 11, 2022
    Buyer
    Core One Labs Inc.
    Target
    Awakened Biosciences Inc.
    Seller
    Shareholders of Awakened Biosciences Inc.
    Industry
    Biotechnology
    Location
    Ontario, Canada
    Type
    Buyout

    Core One Labs Inc. (CSE: COOL) has completed the acquisition of all outstanding share capital of Awakened Biosciences Inc., adding Awakened's provisional patents and novel synthetic psilocybin production technologies to Core One's portfolio. The deal expands Core One's R&D and manufacturing capabilities in psychedelic therapeutics and secures IP that could enable lower-cost, scalable production and potential near-term revenue from non-controlled psilocybin-based compounds.

  • Core One Labs Acquires New Path Laboratories
    December 23, 2021
    Buyer
    Core One Labs Inc.
    Target
    New Path Laboratories Inc.
    Seller
    Shareholders of New Path Laboratories Inc.
    Industry
    Food & Beverage
    Location
    British Columbia, Canada
    Type
    Buyout

    Core One Labs Inc. has completed the acquisition of all outstanding share capital of New Path Laboratories Inc., a British Columbia-based developer and manufacturer of natural health products and functional mushroom dietary supplements. The deal was paid in common shares of Core One and is intended to expand Core One's presence in the functional mushrooms market and add retail distribution channels to generate sales revenue.

  • Core One Labs Acquires Akome Biotech
    April 29, 2021
    Buyer
    Core One Labs Inc.
    Target
    Akome Biotech Ltd.
    Seller
    Existing shareholders of Akome Biotech
    Industry
    Biotechnology
    Location
    Catalonia, Spain
    Type
    Buyout

    Core One Labs Inc. (CSE: COOL), a Vancouver-based biotechnology company, entered into a definitive share purchase agreement to acquire all outstanding share capital of Akome Biotech Ltd. Core One will issue 3,500,000 common shares to Akome’s shareholders as consideration; the acquisition expands Core One’s psychedelic-therapeutics R&D capabilities targeting stroke, Alzheimer’s, Parkinson’s and depression.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 2 tracked deals by Core One Labs. Food & Beverage Buyers & Acquisitions 1 tracked deal by Core One Labs.

Selling a company? Get in front of buyers like Core One Labs

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →